Abstract of the Disclosure

A treatment for glomerulonephritis with (\pm) -1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate.

This invention relates toprophylactic or therapeutic drug for diabetic nephropathy or glomerulonephritis, comprising, as an active ingredient, a compound or salt thereof represented by general formula (I)

$$X$$
 $(CH_2)_n$
 $Y-R^1$
 R^3

wherein R¹-stands for H or an optionally substituted hydrocarbon residue; R²-stands for an optionally esterified carboxyl group; R³-stands for a group actually or potentially capable of forming an anion; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic chain length of two or less; n stands for 1 or 2; ring A stands for a benzene ring having an optional substituent in addition to R²; Y stands for a bond, O-, S(O)_m—(wherein m stands for 0, 1 or 2), or N(R⁴)—(wherein R⁴-stands for H or an optionally substituted alkyl group).